Development and Validation of a New Prognostic System for Patients with Hepatocellular Carcinoma

PLoS Medicine

Volumn 13, Issue 4, 2016, Pages

  Farinati, Fabio ^a   Vitale, Alessandro ^a   Spolverato, Gaya ^a   Pawlik, Timothy M ^b   Huo, Teh La ^c,d   Lee, Yun Hsuan ^c,d   Frigo, Anna Chiara ^a   Giacomin, Anna ^a   Giannini, Edoardo G ^e   Ciccarese, Francesca ^f   Piscaglia, Fabio ^g   Rapaccini, Gian Lodovico ^h   Di Marco, Mariella ⁱ   Caturelli, Eugenio ^j   Zoli, Marco ^g   Borzio, Franco ^k   Cabibbo, Giuseppe ^l   Felder, Martina ^m   Sacco, Rodolfo ⁿ   Morisco, Filomena ^o   Biasini, Elisabetta ^p   Foschi, Francesco Giuseppe ^q   Gasbarrini, Antonio ^r   Svegliati Baroni, Gianluca ^s   Virdone, Roberto ^t   Masotto, Alberto ^u   Trevisani, Franco ^g   Cillo, Umberto ^a   Biselli, Maurizio ^g   Bolondi, Luigi ^g   Bucci, Laura ^g   Cucchetti, Alessandro ^g   Garuti, Francesca ^g   Gramenzi, Annagiulia ^g   Lenzi, Barbara ^g   Magalotti, Donatella ^g   Pecorelli, Anna ^g   Serra, Carla ^g   Venerandi, Laura ^g   Gazzola, Alessia ^a   Murer, Francesca ^a   Pozzan, Caterina ^a   Vanin, Veronica ^a   Del Poggio, Paolo ^v   Olmi, Stefano ^v   Balsamo, Claudia ⁱ   Vavassori, Elena ⁱ   Benvegnù, Luisa ^a   Capelli, Alberta ^w   Golfieri, Rita ^w   Mosconi, Cristina ^w   Renzulli, Matteo ^w   Bosco, Giulia ^h   Roselli, Paola ^j   Dell'Isola, Serena ^j   Ialungo, Anna Maria ^j   Rastrelli, Elena ^j   Moscatelli, Alessandro ^x   Pellegatta, Gaia ^x   Picciotto, Antonino ^x   Savarino, Vincenzo ^x   Barcellona, Maria Rosa ^l   Cammà, Calogero ^l   Costantino, Andrea ^l   Affronti, Andrea ^t   Mega, Andrea ^m   Rinninella, Emanuele ^r   Mismas, Valeria ⁿ   Dall'Aglio, Anna Chiara ^q   Feletti, Valentina ^q   Lanzi, Arianna ^q   Mirici Cappa, Federica ^q   Neri, Elga ^q   Stefanini, Giuseppe Francesco ^q   Tamberi, Stefano ^q   Missale, Gabriele ^y   Porro, Emanuela ^y   Guarino, Maria ^o   Schiadà, Laura ^s   Cuttone, Filiana ^t   Chiaramonte, Maria ^u   Marchetti, Fabiana ^u   Valerio, Matteo ^u   more..

^a UNIVERSITY OF PADOVA   (Italy)

^b JOHNS HOPKINS HOSPITAL   (United States)

^c NATIONAL YANG MING UNIVERSITY   (Taiwan)

^d TAIPEI VETERANS GENERAL HOSPITAL   (Taiwan)

^e UNIVERSITY OF GENOA   (Italy)

^f San Marco Hospital   (Italy)

^g UNIVERSITY OF BOLOGNA   (Italy)

^h CATHOLIC UNIVERSITY   (Italy)

ⁱ BOLOGNINI HOSPITAL   (Italy)

^j BELCOLLE HOSPITAL   (Italy)

^k FATEBENEFRATELLI HOSPITAL   (Italy)

^l UNIVERSITY OF PALERMO   (Italy)

^m CENTRAL HOSPITAL OF BOLZANO   (Italy)

ⁿ UNIVERSITY HOSPITAL OF PISA   (Italy)

^o UNIVERSITY OF NAPLES FEDERICO II   (Italy)

^p UNIVERSITY OF PARMA   (Italy)

^q Ospedale per gli Infermi di Faenza   (Italy)

^r FONDAZIONE POLICLINICO UNIVERSITARIO A GEMELLI IRCCS   (Italy)

^s UNIVERSITÀ POLITECNICA DELLE MARCHE   (Italy)

^t Laboratorio di Genetica Molecolare Ospedali Riuniti Villa Sofia V Cervello   (Italy)

^u SACRO CUORE DON CALABRIA HOSPITAL   (Italy)

^v UnitàOperativadiChirurgia PoliclinicoS Marco   (Italy)

^w UNIVERSITY OF BOLOGNA   (Italy)

^x UNIVERSITY OF GENOA   (Italy)

^y UNIVERSITY HOSPITAL OF PARMA   (Italy)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; AGED; ALPHA FETOPROTEIN BLOOD LEVEL; ARTICLE; CALIBRATION; CHILD PUGH SCORE; EVALUATION AND FOLLOW UP; FEMALE; HUMAN; INTERNATIONAL PROGNOSTIC SCORING SYSTEM; LIVER CELL CARCINOMA; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; PERCEPTIVE DISCRIMINATION; PERFORMANCE; SCORING SYSTEM; STATISTICS; VALIDATION PROCESS; BLOOD; CANCER STAGING; CLINICAL TRIAL; DECISION SUPPORT SYSTEM; FACTUAL DATABASE; ITALY; LIVER TUMOR; MORTALITY; MULTICENTER STUDY; MULTIPLE CANCER; PATHOLOGY; PREDICTIVE VALUE; PROCEDURES; REPRODUCIBILITY; RETROSPECTIVE STUDY; RISK ASSESSMENT; RISK FACTOR; SECONDARY; SURVIVAL ANALYSIS; TAIWAN; TIME FACTOR; TUMOR INVASION; TUMOR VOLUME; VALIDATION STUDY;

AFP PROTEIN, HUMAN; ALPHA FETOPROTEIN;

AGED; ALPHA-FETOPROTEINS; CARCINOMA, HEPATOCELLULAR; DATABASES, FACTUAL; DECISION SUPPORT TECHNIQUES; FEMALE; HUMANS; ITALY; LIVER NEOPLASMS; MALE; MIDDLE AGED; NEOPLASM INVASIVENESS; NEOPLASM STAGING; NEOPLASMS, MULTIPLE PRIMARY; PREDICTIVE VALUE OF TESTS; REPRODUCIBILITY OF RESULTS; RETROSPECTIVE STUDIES; RISK ASSESSMENT; RISK FACTORS; SURVIVAL ANALYSIS; TAIWAN; TIME FACTORS; TUMOR BURDEN;

EID: 84964756559     PISSN: 15491277     EISSN: 15491676     Source Type: Journal    
DOI: 10.1371/journal.pmed.1002006     Document Type: Article

References (37)

1. Zhao C, Nguyen MH, Hepatocellular carcinoma screening and surveillance: practice guidelines and real-life practice. J Clin Gastroenterol. 2016;50:120–133. 26583266
2. Lafaro KJ, Demirjian AN, Pawlik TM, Epidemiology of hepatocellular carcinoma. Surg Oncol Clin N Am. 2015;24:1–17. doi: 10.1016/j.soc.2014.09.00125444466
3. Bruix J, Sherman M, Llovet JM, Beaugrand M, Lencioni R, Burroughs AK, et al. Clinical management of hepatocellular carcinoma. Conclusions of the Barcelona-2000 EASL conference. European Association for the Study of the Liver. J Hepatol. 2001;35:421–430. 11592607
4. European Association for the Study of the LiverEuropean Organisation for Research and Treatment of CancerEASL-EORTC clinical practice guidelines: management of hepatocellular carcinoma. J Hepatol. 2012;56:908–943. doi: 10.1016/j.jhep.2011.12.00122424438
5. Bruix J, Sherman M, Practice Guidelines Committee of the American Association for the Study of Liver DiseasesManagement of hepatocellular carcinoma. Hepatology. 2005;42:1208–1236. 16250051
6. Llovet JM, Bru C, Bruix J, Prognosis of hepatocellular carcinoma: the BCLC staging classification. Semin Liver Dis. 1999;19:329–338. 10518312
7. United Network for Organ Sharing. Important policy notice. 2011 Dec 15 [cited 5 Mar 2015]. Available: http://optn.transplant.hrsa.gov/SharedContentDocuments/2011-11_Policy_Notice.pdf.
8. Yau T, Tang VY, Yao TJ, Fan ST, Lo CM, Poon RT, Development of Hong Kong Liver Cancer staging system with treatment stratification for patients with hepatocellular carcinoma. Gastroenterology. 2014;146:1691–1700. doi: 10.1053/j.gastro.2014.02.03224583061
9. Edge S, Byrd DR, Compton CC, Fritz AG, Greene FL, Trotti A, AJCC cancer staging manual. 7th edition. New York: Springer; 2010.
10. Kim BH, Park JW, Nam BH, Kwak HW, Kim WR, Validation of a model to estimate survival in ambulatory patients with hepatocellular carcinoma: a single-centre cohort study. Liver Int. 2014;34:e317–e323. doi: 10.1111/liv.1251924606128
11. Okuda K, Ohtsuki T, Obata H, Tomimatsu M, Okazaki N, Hasegawa H, et al. Natural history of hepatocellular carcinoma and prognosis in relation to treatment. Study of 850 patients. Cancer. 1985;56:918–928. 2990661
12. A new prognostic system for hepatocellular carcinoma: a retrospective study of 435 patients: the Cancer of the Liver Italian Program (CLIP) investigators. Hepatology. 1998;28:751–755. 9731568
13. Chevret S, Trinchet JC, Mathieu D, Rached AA, Beaugrand M, Chastang C, A new prognostic classification for predicting survival in patients with hepatocellular carcinoma. Groupe d’Etude et de Traitement du Carcinome Hepatocellulaire. J Hepatol. 1999;31:133–141. 10424293
14. Leung TW, Tang AM, Zee B, Lau WY, Lai PB, Leung KL, et al. Construction of the Chinese University Prognostic Index for hepatocellular carcinoma and comparison with the TNM staging system, the Okuda staging system, and the Cancer of the Liver Italian Program staging system: a study based on 926 patients. Cancer. 2002;94:1760–1769. 11920539
15. Kudo M, Chung H, Osaki Y, Prognostic staging system for hepatocellular carcinoma (CLIP score): its value and limitations, and a proposal for a new staging system, the Japan Integrated Staging Score (JIS score). J Gastroenterol. 2003;38:207–215. 12673442
16. Tateishi R, Yoshida H, Shiina S, Imamura H, Hasegawa K, Teratani T, et al. Proposal of a new prognostic model for hepatocellular carcinoma: an analysis of 403 patients. Gut. 2005;54:419–425. 15710994
17. Yang JD, Kim WR, Park KW, Chaiteerakij R, Kim B, Sanderson SO, et al. Model to estimate survival in ambulatory patients with hepatocellular carcinoma. Hepatology. 2012;56:614–621. doi: 10.1002/hep.2568022370914
18. Child CG, Turcotte JG, Surgery and portal hypertension. Major Probl Clin Surg. 1964;1:1–85. 4950264
19. Pugh RN, Murray-Lyon IM, Dawson JL, Pietroni MC, Williams R, Transection of the oesophagus for bleeding oesophageal varices. Br J Surg. 1973;60:646–649. 4541913
20. Hsu CY, Lee YH, Hsia CY, Huang YH, Su CW, Lin HC, et al. Performance status in patients with hepatocellular carcinoma: determinants, prognostic impact, and ability to improve the Barcelona Clinic Liver Cancer system. Hepatology. 2013;57:112–119. doi: 10.1002/hep.2595022806819
21. Baraldi AN, Enders CK, An introduction to modern missing data analyses. J Sch Psychol. 2010;48:5–37. doi: 10.1016/j.jsp.2009.10.00120006986
22. Steyerberg EW, Vickers AJ, Cook NR, Gerds T, Gonen M, Obuchowski N, et al. Assessing the performance of prediction models: a framework for traditional and novel measures. Epidemiology. 2010;21:128–138. 20010215
23. Bolondi L, Burroughs A, Dufour JF, Galle PR, Mazzaferro V, Piscaglia F, et al. Heterogeneity of patients with intermediate (BCLC B) hepatocellular carcinoma: proposal for a subclassification to facilitate treatment decisions. Semin Liver Dis. 2012;32:348–359. doi: 10.1055/s-0032-132990623397536
24. Duvoux C, Roudot-Thoraval F, Decaens T, Pessione F, Badran H, Piardi T, et al. Liver transplantation for hepatocellular carcinoma: a model including alpha-fetoprotein improves the performance of Milan criteria. Gastroenterology. 2012;143:986–994. doi: 10.1053/j.gastro.2012.05.05222750200
25. Hameed B, Mehta N, Sapisochin G, Roberts JP, Yao FY, Alpha-fetoprotein level > 1000 ng/mL as an exclusion criterion for liver transplantation in patients with hepatocellular carcinoma meeting the Milan criteria. Liver Transpl. 2014;20:945–951. doi: 10.1002/lt.2390424797281
26. Stone M, Armitage P, Colton T, Akaike’s criteria. In: Encyclopedia of biostatistics. Chichester: Wiley; 1998. pp. 123–124.
27. Bolondi L, Cillo U, Colombo M, Craxi A, Farinati F, Giannini EG, et al. Position paper of the Italian Association for the Study of the Liver (AISF): the multidisciplinary clinical approach to hepatocellular carcinoma. Dig Liver Dis. 2013;45:712–723. 23769756
28. Freeman RB, Edwards EB, Harper AM, Waiting list removal rates among patients with chronic and malignant liver diseases. Am J Transplant. 2006;6:1416–1421. 16686765
29. Johnson PJ, Berhane S, Kagebayashi C, Satomura S, Teng M, Reeves HL, et al. Assessment of liver function in patients with hepatocellular carcinoma: a new evidence-based approach—the ALBI grade. J Clin Oncol. 2015;33:550–558. doi: 10.1200/JCO.2014.57.915125512453
30. Roayaie S, Jibara G, Tabrizian P, Park JW, Yang J, Yan L, et al. The role of hepatic resection in the treatment of hepatocellular cancer. Hepatology. 2015;62:440–451. doi: 10.1002/hep.2774525678263
31. Vitale A, Burra P, Frigo AC, Trevisani F, Farinati F, Spolverato G, et al. Survival benefit of liver resection for patients with hepatocellular carcinoma across different Barcelona Clinic Liver Cancer stages: a multicentre study. J Hepatol. 2015;62:617–624. doi: 10.1016/j.jhep.2014.10.03725450706
32. Torzilli G, Belghiti J, Kokudo N, Takayama T, Capussotti L, Nuzzo G, et al. A snapshot of the effective indications and results of surgery for hepatocellular carcinoma in tertiary referral centers: is it adherent to the EASL/AASLD recommendations?: an observational study of the HCC East-West study group. Ann Surg. 2013;257:929–937. 23426336
33. Zhong JH, Ke Y, Gong WF, Xiang BD, Ma L, Ye XP, Peng T, et al. Hepatic resection associated with good survival for selected patients with intermediate and advanced-stage hepatocellular carcinoma. Ann Surg. 2014;260:329–340. 24096763
34. Peng ZW, Zhang YJ, Chen MS, Xu L, Liang HH, Lin XJ, et al. Radiofrequency ablation with or without transcatheter arterial chemoembolization in the treatment of hepatocellular carcinoma: a prospective randomized trial. J Clin Oncol. 2013;31: 426–432. doi: 10.1200/JCO.2012.42.993623269991
35. Wang Y, Deng T, Zeng L, Chen W, Efficacy and safety of radiofrequency ablation and transcatheter arterial chemoembolization for treatment of hepatocellular carcinoma: A meta-analysis. Hepatol Res. 2015;46:58–71. doi: 10.1111/hepr.1256826265000
36. McGlynn KA, Petrick JL, London WT, Global epidemiology of hepatocellular carcinoma: an emphasis on demographic and regional variability. Clin Liver Dis. 2015;19:223–238. 25921660
37. Liu PH, Hsu CY, Hsia CY, Lee YH, Su CW, Huang YH, et al. Prognosis of hepatocellular carcinoma: assessment of eleven staging systems. J Hepatol. 2016;64:601–608. doi: 10.1016/j.jhep.2015.10.02926551516